It appears you don't have support to open PDFs in this web browser. To view this file, Open with your PDF reader
Abstract
Phox homology (PX) domains are membrane interacting domains that bind to phosphatidylinositol phospholipids or phosphoinositides, markers of organelle identity in the endocytic system. Although many PX domains bind the canonical endosome-enriched lipid PtdIns3P, others interact with alternative phosphoinositides, and a precise understanding of how these specificities arise has remained elusive. Here we systematically screen all human PX domains for their phospholipid preferences using liposome binding assays, biolayer interferometry and isothermal titration calorimetry. These analyses define four distinct classes of human PX domains that either bind specifically to PtdIns3P, non-specifically to various di- and tri-phosphorylated phosphoinositides, bind both PtdIns3P and other phosphoinositides, or associate with none of the lipids tested. A comprehensive evaluation of PX domain structures reveals two distinct binding sites that explain these specificities, providing a basis for defining and predicting the functional membrane interactions of the entire PX domain protein family.
Phox homology (PX) domains are membrane interacting domains that bind to various lipids. Here authors screen all human PX domains systematically for their phospholipid preferences and define four classes and provide the basis for defining and predicting functional PX-membrane interactions.
You have requested "on-the-fly" machine translation of selected content from our databases. This functionality is provided solely for your convenience and is in no way intended to replace human translation. Show full disclaimer
Neither ProQuest nor its licensors make any representations or warranties with respect to the translations. The translations are automatically generated "AS IS" and "AS AVAILABLE" and are not retained in our systems. PROQUEST AND ITS LICENSORS SPECIFICALLY DISCLAIM ANY AND ALL EXPRESS OR IMPLIED WARRANTIES, INCLUDING WITHOUT LIMITATION, ANY WARRANTIES FOR AVAILABILITY, ACCURACY, TIMELINESS, COMPLETENESS, NON-INFRINGMENT, MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE. Your use of the translations is subject to all use restrictions contained in your Electronic Products License Agreement and by using the translation functionality you agree to forgo any and all claims against ProQuest or its licensors for your use of the translation functionality and any output derived there from. Hide full disclaimer
Details



1 The University of Queensland, Institute for Molecular Bioscience, St. Lucia, Australia (GRID:grid.1003.2) (ISNI:0000 0000 9320 7537)
2 The University of Queensland, Institute for Molecular Bioscience, St. Lucia, Australia (GRID:grid.1003.2) (ISNI:0000 0000 9320 7537); Integrated Structural Biology Grenoble, Grenoble, France (GRID:grid.1003.2)
3 University of Texas Southwestern Medical Center, Department of Cell Biology, Dallas, USA (GRID:grid.267313.2) (ISNI:0000 0000 9482 7121)
4 The University of Queensland, Centre for Advanced Imaging and School of Chemistry and Molecular Biology, St. Lucia, Australia (GRID:grid.1003.2) (ISNI:0000 0000 9320 7537)
5 The University of Queensland, School of Biomedical Sciences, Faculty of Medicine, St. Lucia, Australia (GRID:grid.1003.2) (ISNI:0000 0000 9320 7537)
6 Monash University, Medicinal Chemistry, Monash Institute of Pharmaceutical Sciences, Parkville, Australia (GRID:grid.1002.3) (ISNI:0000 0004 1936 7857)
7 The University of Queensland, Institute for Molecular Bioscience, St. Lucia, Australia (GRID:grid.1003.2) (ISNI:0000 0000 9320 7537); The University of Queensland, School of Biomedical Sciences, Faculty of Medicine, St. Lucia, Australia (GRID:grid.1003.2) (ISNI:0000 0000 9320 7537)